Drug Name: TruqapActive Ingredient: capivasertibIndication: An AKT inhibitor used in combination with fulvestrant for the treatment of advanced HR-positive breast cancerApproval Date: 11/16/2023Company: AstraZenecaMore: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-fulvestrant-breast-cancer Related Post navigation Defencath as a Catheter Lock Solution Progress in AI-Driven Drug Discovery: Overcoming Limited Access to High-Quality Data